Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitroglycerin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitroglycerin SCHEMBL9154265 | 1.00 | PTGS2 (0.41) | PTGS2PTGS1CA5ACA5BALDH1A1 | |
| Nitroglycerin SCHEMBL920644 | 0.93 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL15421 | 0.93 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL10424193 | 0.91 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL7752036 | 0.91 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL28118295 | 0.91 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL7752031 | 0.91 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL3640987 | 0.91 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL3640991 | 0.91 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL28723109 | 0.91 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3554483-B1 | REDUCING SIDE EFFECTS OF SHORT ACTING NO DONORS | G POHL BOSKAMP GMBH & CO KG (DE) | 2024-01-31 | — | — | EP | disclosed |
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115003279-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-113679682-A | Nitroglycerin sublingual tablet and preparation method thereof | 珠海润都制药股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-112741822-A | Transdermal patch delivery system for the dermal or mucosal release of active substances | 江苏集萃新型药物制剂技术研究所有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-111655239-A | Shear stress sensitive liposomes | 巴塞尔大学 | 2020-09-11 | — | — | CN | disclosed |
| US-20200276145-A1 | REDUCING SIDE EFFECTS OF SHORT ACTING NO DONORS | G. POHL-BOSKAMP GMBH & CO. KG (DE) | 2020-09-03 | — | — | US | disclosed |
| CN-105744983-B | Device and method for sustained release of therapeutic agents of low water solubility in solubilizing agents | 纳米医学系统公司 | 2019-12-27 | — | — | CN | disclosed |
| EP-3554483-A1 | REDUCING SIDE EFFECTS OF SHORT ACTING NO DONORS | G. Pohl-Boskamp GmbH & Co. KG (DE) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109131-A1 | REDUCING SIDE EFFECTS OF SHORT ACTING NO DONORS | G. POHL-BOSKAMP GMBH & CO. KG (DE) | 2018-06-21 | — | — | WO | disclosed |
| WO-2012088597-A1 | NITRIC OXIDE AMINO ACID ESTERS FOR ENHANCEMENT OF PHYSICAL OR MUSCULAR PERFORMANCE AND THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES | ORAL DELIVERY TECHNOLOGY LTD. (CA) | 2012-07-05 | — | — | WO | disclosed |
| CN-1172665-C | Combined medicinal preparation of sodium/hydrogen exchange-pump inhibitor and medicine for treatment of angiocardiopathy | ���ĵ�˹ҩ��¹�����˾ | 2004-10-27 | — | — | CN | disclosed |
| US-6573288-B1 | Compounds are inhibitors of the sodium-dependent bicarbonate/chloride ion exchanger which can be used as medicines for the prophylaxis or treatment of a wide range of diseases, for example the treatment and/or prophylaxis of | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-06-03 | — | — | US | disclosed |
| US-6369069-B1 | CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| US-5968978-A | ANTIARRYTHMIA AGENTS, ANTIISCHEMIC AGENTS, INHIBIT PROLIFERATION OF CELLS | HOECHST MARION ROUSSEL DEUTSCHLAND (DE) | 1999-10-19 | — | — | US | disclosed |
| CN-1209316-A | Combined medicinal preparation of sodium/hydrogen exchange-pump inhibitor and medicine for treatment of angiocardiopathy | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-03-03 | — | — | CN | disclosed |